DDInter1664 DDInter1676
Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Sevoflurane {u} (Compound) resembles {v} (Compound) Perflutren
Sevoflurane {u} (Compound) binds {v} (Gene) GABRP
Sevoflurane {u} (Compound) is included by {v} (Pharmacologic Class) General Anesthesia
Sevoflurane {u} (Compound) causes {v} (Side Effect) Obstructive airways disorder
Sevoflurane {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Sevoflurane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Sevoflurane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Granisetron
Sevoflurane {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Sevoflurane {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Sevoflurane (Compound) resembles Perflutren (Compound)
Sevoflurane (Compound) binds GABRP (Gene)
Sevoflurane (Compound) is included by General Anesthesia (Pharmacologic Class)
Sevoflurane (Compound) causes Obstructive airways disorder (Side Effect)
Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Sevoflurane may lead to a major life threatening interaction when taken with Halofantrine
Sevoflurane may lead to a major life threatening interaction when taken with Pasireotide